Polymyositis and dermatomyositis laboratory findings: Difference between revisions
Line 29: | Line 29: | ||
{| class="wikitable" | {| class="wikitable" | ||
!Autoantibody | !Autoantibody | ||
!Association | !Association | ||
!Percentage | !Percentage | ||
|- | |- | ||
|Histidyl-tRNA synthetase (anti-Jo-1) | |Histidyl-tRNA synthetase (anti-Jo-1) | ||
| | | | ||
* Antisynthetase syndrome | * Antisynthetase syndrome | ||
* Flare up in spring | * Flare up in spring | ||
* Epstein-Barr virus (EBV), adenovirus, and influenza infection | * Epstein-Barr virus (EBV), adenovirus, and influenza infection | ||
| | | | ||
|- | |- | ||
Line 50: | Line 42: | ||
| | | | ||
* Severe dermatomyositis rash without significant lung involvement | * Severe dermatomyositis rash without significant lung involvement | ||
| | | | ||
|- | |- | ||
|Signal recognition particle (anti-SRP) | |Signal recognition particle (anti-SRP) | ||
| | | | ||
* Flare up in fall | * Flare up in fall | ||
| | | | ||
|- | |- | ||
|Alanyl-tRNA synthetase (PL-12) | |Alanyl-tRNA synthetase (PL-12) | ||
| | | | ||
* Epstein-Barr virus (EBV), adenovirus, and influenza infection | * Epstein-Barr virus (EBV), adenovirus, and influenza infection | ||
| | | | ||
|- | |- | ||
|Transcriptional intermediary factor 1-gamma (TIF-1γ) | |Transcriptional intermediary factor 1-gamma (TIF-1γ) | ||
| | | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
* Juvenile dermatomyositis | * Juvenile dermatomyositis | ||
| | | | ||
|- | |- | ||
|Nuclear matrix protein (NXP-2) | |Nuclear matrix protein (NXP-2) | ||
| | | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
* Juvenile dermatomyositis | * Juvenile dermatomyositis | ||
| | | | ||
|- | |- | ||
|Anti-small ubiquitin-like modifier activating enzyme (anti-SAE) | |Anti-small ubiquitin-like modifier activating enzyme (anti-SAE) | ||
| | | | ||
* Cancer-associated myositis | * Cancer-associated myositis | ||
| | | | ||
|- | |- | ||
|Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) | |Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) | ||
| | | | ||
* Statin-associated necrotizing autoimmune myopathy (SANAM) | * Statin-associated necrotizing autoimmune myopathy (SANAM) | ||
|6% | |6% | ||
|- | |- | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | |
Revision as of 16:04, 5 April 2018
Polymyositis and dermatomyositis Microchapters |
Differentiating Polymyositis and dermatomyositis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Polymyositis and dermatomyositis laboratory findings On the Web |
American Roentgen Ray Society Images of Polymyositis and dermatomyositis laboratory findings |
Polymyositis and dermatomyositis laboratory findings in the news |
Blogs on Polymyositis and dermatomyositis laboratory findings |
Risk calculators and risk factors for Polymyositis and dermatomyositis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal for patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Laboratory Findings
- Laboratory findings consistent with the diagnosis of polymyositis and dermatomyositis include:[1]
Myositis-specific autoantibodies
Autoantibody | Association | Percentage |
---|---|---|
Histidyl-tRNA synthetase (anti-Jo-1) |
|
|
Chromodomain helicase DNA binding protein 4 (Mi-2) |
|
|
Signal recognition particle (anti-SRP) |
|
|
Alanyl-tRNA synthetase (PL-12) |
|
|
Transcriptional intermediary factor 1-gamma (TIF-1γ) |
|
|
Nuclear matrix protein (NXP-2) |
|
|
Anti-small ubiquitin-like modifier activating enzyme (anti-SAE) |
|
|
Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) |
|
6% |